Table III.
Adverse events per dose cohort (cycles other than 1).
| Erlotinib dose | MO17974 trial (n=12)
|
Ml18511 trial (n=9)
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 100 mg (n=3) | 125 mg (n=3) | 150 mg (n=6) | 100 mg (n=3) | 125 mg (n=3) | 150 mg (n=6) | 100 mg (n=6) | 150 mg (n=3) | 100 mg (n=6) | 150 mg (n=3) | |
|
|
|
|
|
|||||||
| Grade 1–2 | Grade 3–4 | Grade 1–2 | Grade 3–4 | |||||||
| Mucositis | 1 | 1 | 2 | 1 | - | - | ||||
| Diarrhea | 3 | - | 2 | 1 | - | 1 | 4 | 2 | 1 | 1 |
| Asthenia | 2 | 2 | - | - | - | - | 2 | - | 1 | |
| Nausea | 2 | 2 | 4 | - | - | - | 1 | - | 2 | - |
| Vomiting | - | - | 1 | - | ||||||
| Anemia | - | - | 1 | 1 | - | - | - | - | 1 | - |
| Neutropenia | - | - | 1 | 2 | 2 | 2 | 1 | 1 | - | - |
| Constipation | 2 | 1 | 1 | - | - | - | ||||
| Neurotoxicity | 1 | 2 | 2 | 1 | 1 | - | 1 | 1 | - | - |
| Urinary infection | - | 2 | - | - | - | - | ||||
| Numbness | 1 | - | - | - | - | - | ||||
| Abdominal pain | - | - | 1 | - | - | - | ||||
| Fever | - | - | - | - | - | 1 | ||||
| Transaminitis | - | 1 | 2 | - | - | - | ||||
| Thrombocytopenia | 1 | - | 1 | 1 | 1 | - | ||||
| Rectal bleeding | 1 | - | - | - | - | - | - | 1 | 1 | - |
| Skin rash | 3 | 2 | 1 | - | - | - | 4 | 1 | - | - |
| Anorexia | 3 | - | - | - | ||||||
| Epistaxis | - | - | - | - | - | 1 | - | - | - | |